Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for HCC Which is Unresectable But Confined to the Liver

NCT03116984 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT03116984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03116984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for HCC Which is Unresectable But Confined to the Liver
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
January 1, 2017
Completion date
December 31, 2020
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma